BioDrugs Journal

BioDrugs (2024 IF 6.9) covers the development and therapeutic application of biotechnology-based pharmaceuticals for the treatment of human disease.

[BioDrugs Journal @BioDrugsJournal]

This manuscript evaluated the impact of demand- and supply-side policies on biosimilar market penetration and identified effective strategies for promoting biosimilar uptake in eight high-income countries.
#biosimilars #marketpenetration #OpenAccess
https://t.co/Gw5R1BmpeB

[BioDrugs Journal @BioDrugsJournal]

This study evaluated quality attributes of multiple lots of reference products and their biosimilars approved in Japan.
#biosimilars #qualityattributes #openaccess
https://t.co/pcOstPKJDi

[BioDrugs Journal @BioDrugsJournal]

This review presents current and future treatment options for Fabry disease, with advantages and disadvantages of the different treatment options.
#FabryDisease #genetherapy #OpenAccess
https://t.co/nWtcFbs5J2

[BioDrugs Journal @BioDrugsJournal]

This study investigates the structural origins and functional implications of charge heterogeneity in two therapeutic IgG2 antibodies using free-flow isoelectric focusing (FF-IEF).
#chargevariants #monoclonalantibodies #isoelectricfocusing
https://t.co/zlsnJqX5tC

[BioDrugs Journal @BioDrugsJournal]

This narrative review provides insights into the efficacy and safety of transitioning to and among adalimumab biosimilars in adult patients from clinical studies and real-world evidence from outside the USA.
#biosimilars #adalilumab #realworldevidence
https://t.co/0HsNsKxQpT

[BioDrugs Journal @BioDrugsJournal]

This review summarizes the recent advances in the knowledge of IgM biogenesis and structure and discusses the therapeutic opportunities of IgM over IgG and outstanding challenges.
#antibody #immunoglobulinM #monoclonalAntibodies
https://t.co/CCdc18sRda

[BioDrugs Journal @BioDrugsJournal]

This study provides real-world evidence on the effectiveness and safety of spesolimab treatment for GPP flares, based on a case series of Portuguese patients.
#GeneralizedPustularPsoriasis #spesolimab #il36
https://t.co/iD6B00xwRu

[BioDrugs Journal @BioDrugsJournal]

This article highlights the evolution of nucleic acid-based drug development, focusing on the pioneering agents fomivirsen, patisiran, & givosiran, & discusses the ongoing challenges in advancing these therapeutics & vaccines
#nucleicaciddrugs #genetherapy
https://t.co/F4GqO23S2q

[BioDrugs Journal @BioDrugsJournal]

CM326 is a novel monoclonal antibody targeting TSLP under investigation for the treatment of several type 2 inflammatory diseases. This study presents preclinical characterization and phase I human trials.
#thymicstromallymphopoietin #inflammatorydisease
https://t.co/oMKRFP59bU

[BioDrugs Journal @BioDrugsJournal]

In this cohort study of older patients with immune-mediated inflammatory diseases, Gianluca Trifirò et al found a 6-fold increase in use of biologics from 2010 to 2022, and a treatment persistence of ~50% at one year.
#OpenAccess #biologics #olderadults
https://t.co/LIKSbUrMVW

[BioDrugs Journal @BioDrugsJournal]

This study investigated the clinical safety, tolerability, pharmacokinetics & preliminary pharmacodynamics of HEC88473, a 2nd generation GLP-1/FGF21 agonist, in a phase I, single-ascending dose trial with healthy & obese subjects
#glp1 #FGF21 #FirstInHuman
https://t.co/rE8DlJi4mi

[BioDrugs Journal @BioDrugsJournal]

Torleif Tollefsrud Gjølberg and colleagues describe FcRn biology, and give an overview of the current clinical pipeline of FcRn antagonists in autoimmune diseases.
#neonatalFcReceptor #autoimmunedisease #OpenAccess
https://t.co/SvOaWbuBVs

[BioDrugs Journal @BioDrugsJournal]

This review focuses on the biogenesis of extracellular vesicles (EVs), their role in transplant immunology, and how immunosuppressive drugs might influence these processes.
#extracellularvesicles #organtransplant #transplantrejection #OpenAccess
https://t.co/xlErVs8DR8

[BioDrugs Journal @BioDrugsJournal]

This review explores the basic structure, preclinical principles, clinical trial progress, and challenges of multispecific antibodies targeting PD-1/PD-L1 in tumor therapy.
#multispecificantibodies #BispecificAntibodies #CancerImmunotherapy
https://t.co/2mTd8KbsIy

[BioDrugs Journal @BioDrugsJournal]

Structure activity relationship studies of the biosimilar BAT1806/BIIB800 and reference tocilizumab were conducted to assess the potential impact of observed minor differences in quality attributes
#biosimilarity #Structureactivity #Tocilizumab #openaccess
https://t.co/G17OZww26V

[BioDrugs Journal @BioDrugsJournal]

Findings from a targeted review have been incorporated into a framework of biosimilar market sustainability dimensions, to be used by stakeholders in decision-making to ensure long-term viability of the market.
#Biosimilar #biosimilarmarket #sustainability
https://t.co/XhZyXbzwWh

[BioDrugs Journal @BioDrugsJournal]

This analysis reviewed biosimilar-promoting policies in 13 OECD countries and examined their impact on biosimilar uptake and expenditure reduction for adalimumab, etanercept, and infliximab.
#biosimilar #tendering #HealthcarePolicy #healthcarecosts
https://t.co/qBDxDM4BWB

[BioDrugs Journal @BioDrugsJournal]

This review highlights the importance of biosimilars of reference eculizumab and their entry for use in patients with paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome.
#Biosimilar #eculizumab #openaccess
https://t.co/xZMkgvttVB

[BioDrugs Journal @BioDrugsJournal]

Alfredo Addeo & colleagues review proposed mechanisms of resistance to immunotherapy with checkpoint inhibitors, & discuss therapeutic strategies designed to prevent primary resistance and counteract acquired resistance.
#immunotherapy #NSCLC #OpenAccess https://t.co/qo1MjjnDSB

[BioDrugs Journal @BioDrugsJournal]

Arthur Rech Tondin & Giacomo Lanzoni provide an overview of current islet replacement strategies for type 1 diabetes, ranging from islet transplantation to stem cell-derived islet cell transplantation.
#diabetes #isletcell #celltherapy #OpenAccess
https://t.co/XtCycRzc4O